Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VECTIBIX vs VEGZELMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.
Metastatic colorectal cancer (m CRC) with wild-type RAS (KRAS and NRAS) as first-line in combination with FOLFOX or as monotherapy after progression,Metastatic colorectal cancer (m CRC) with wild-type RAS as second-line in combination with irinotecan or as monotherapy after failure of irinotecan-based regimens
Metastatic colorectal cancer (first-line with IFL regimen),Metastatic colorectal cancer (first-line with FOLFOX regimen),Metastatic colorectal cancer (second-line with FOLFOX),Non-squamous non-small cell lung cancer (first-line with carboplatin/paclitaxel),Glioblastoma (as single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (with interferon alfa),Cervical cancer (with paclitaxel/cisplatin or paclitaxel/topotecan),Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with paclitaxel, pegylated liposomal doxorubicin, or topotecan),Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with carboplatin/paclitaxel or carboplatin/gemcitabine)
6 mg/kg IV every 14 days.
Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Terminal half-life: 11-14 hours (supports twice-daily dosing; no significant accumulation with normal renal function)
Primarily eliminated via the reticuloendothelial system; not metabolized by cytochrome P450 enzymes; no significant hepatic metabolism.
Bevacizumab undergoes proteolytic degradation via general protein catabolism; no specific metabolic enzymes are involved.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Renal: 70% (metabolites); Fecal: 30% (unchanged drug and metabolites)
Approximately 95% bound, primarily to albumin; minimal binding to other plasma proteins.
97% (primarily to albumin; minimal binding to alpha-1-acid glycoprotein)
Volume of distribution approximately 3.0–4.0 L/kg; suggests extensive tissue distribution and binding to EGFR-expressing cells.
0.3-0.5 L/kg (indicates limited extravascular distribution, primarily confined to plasma and interstitial fluid)
Subcutaneous: Absolute bioavailability approximately 93% relative to intravenous administration.
Subcutaneous: 60-80% (compared to intravenous); oral: not available (not orally bioavailable)
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Insufficient data for severe (Child-Pugh C) hepatic impairment.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; no significant differences in safety or efficacy observed in patients ≥65 years compared to younger adults.
No specific dose adjustment required; monitor for increased incidence of adverse reactions, particularly hypertension and infusion-related reactions.
None.
Serious and sometimes fatal gastrointestinal perforation, wound dehiscence, hemorrhage, and arterial thromboembolic events (including stroke, myocardial infarction) have been reported. Therapy should be discontinued in patients who develop these complications.
Infusion reactions (including severe and fatal), dermatologic toxicity (including severe acneiform dermatitis and infections), increased toxicity with concurrent chemotherapy (especially diarrhea and dehydration), pulmonary fibrosis, hypomagnesemia, ocular toxicity, and potential for fetal harm.
Gastrointestinal perforation; surgery and wound healing complications (discontinue at least 28 days prior to elective surgery); hemorrhage (severe/fatal pulmonary hemorrhage in NSCLC); arterial thromboembolic events; proteinuria; hypertensive crisis; posterior reversible encephalopathy syndrome; infusion reactions; increased risk of ovarian failure; congestive heart failure.
None known.
None known.
No specific food interactions are reported. However, because diarrhoea is common, patients may need to adjust their diet to manage symptoms (e.g., avoid high-fiber, fatty, or spicy foods). Adequate hydration and electrolyte replacement are essential if diarrhoea occurs. No restrictions on grapefruit juice or other CYP3A4 substrates; VECTIBIX is not metabolized by CYP enzymes.
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if also taking CYP3A4 substrates (though not directly studied with VEGZELMA).
Pregnancy Category C. Panitumumab is an Ig G2 monoclonal antibody; Ig G crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EGFR inhibition, there is potential for fetal harm. Animal studies (cynomolgus monkeys) with panitumumab at doses 0.5 to 5 times the clinical exposure (AUC) revealed embryotoxicity and developmental delays (e.g., skeletal malformations, increased abortions). No adequate human studies exist. Use only if potential benefit justifies risk; avoid in pregnancy unless absolutely necessary.
VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratogenicity including increased rates of fetal malformations (e.g., cleft palate, skeletal abnormalities) and embryofetal mortality. In humans, first trimester exposure is not recommended due to risk of teratogenicity. Second and third trimester exposure may be associated with fetal growth restriction, oligohydramnios, and potential fetal renal impairment. No adequate human studies exist; use only if benefit justifies risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk, but panitumumab is a large protein likely degraded in infant GI tract. M/P ratio unknown. Because of potential for serious adverse reactions in nursing infants, advise women to discontinue breastfeeding during treatment and for 2 months after last dose.
No human data on presence in breast milk. Bevacizumab is a large protein (MW ~149 k Da), likely to be excreted in low amounts. M/P ratio unknown. Potential for absorption and systemic effects in infant is low but cannot be excluded. Manufacturer advises to discontinue breastfeeding during therapy and for at least 6 months after last dose.
No pharmacokinetic data in pregnancy; no established dose adjustments. Usual dose: 6 mg/kg IV every 14 days. If used during pregnancy, monitor maternal toxicities closely (e.g., skin, electrolytes) and consider dose reduction or discontinuation based on toxicity. No specific dose modification guidelines exist for pregnancy.
No established dose adjustments for pregnancy. Due to risks, avoid use in pregnancy unless benefit outweighs risk. If used, dose remains same as for non-pregnant adults (e.g., 5 mg/kg IV every 2 weeks). Monitor for increased clearance in second and third trimester; however, no formal PK studies in pregnancy. Consider therapeutic drug monitoring if available.
VECTIBIX (panitumumab) is a fully human monoclonal antibody targeting EGFR. It is indicated for RAS wild-type metastatic colorectal cancer (m CRC). Always confirm RAS wild-type status (no mutations in KRAS/NRAS) before initiation. Infusion reactions are common; premedicate with antihistamine and acetaminophen for first dose. Monitor for dermatologic toxicity (rash, paronychia, dry skin) which is a class effect and may correlate with efficacy. Electrolyte abnormalities, particularly hypomagnesemia, can occur; monitor serum magnesium weekly during therapy and for 8 weeks after completion. Avoid use in patients with RAS mutant tumors due to lack of benefit and potential harm. VECTIBIX is not effective in tumors with BRAF V600E mutation.
VEGZELMA (bevacizumab-adcd) is a bevacizumab biosimilar. Monitor blood pressure regularly due to risk of hypertension. Assess urine protein via dipstick before each dose; hold for ≥2 g proteinuria. Increased risk of arterial thromboembolic events (ATE) in patients >65 years or with prior ATE. Do not administer within 28 days of major surgery. Discontinue for GI perforation, wound dehiscence, or severe hemorrhage.
This medication targets the epidermal growth factor receptor (EGFR) on cancer cells and is used for metastatic colorectal cancer with a specific genetic profile (RAS wild-type).,You will need genetic testing for RAS mutations (KRAS/NRAS) before starting treatment to ensure the drug is appropriate.,Common side effects include skin rash, dry skin, itching, nail infections, and diarrhea. The skin rash may be a sign the drug is working but requires management.,Report any signs of infusion reaction (chills, fever, shortness of breath, flushing) during or after the infusion.,Serious side effects include severe infusion reactions, lung inflammation (interstitial lung disease), and low magnesium levels (muscle cramps, fatigue, irregular heartbeat). You will have regular blood tests to monitor magnesium and other electrolytes.,Avoid sun exposure and use sunscreen, as the drug increases skin sensitivity to sunlight.,Drink plenty of fluids to prevent dehydration from diarrhea, and notify your doctor if diarrhea is severe or persistent.,Do not receive any vaccines without consulting your doctor, especially live vaccines.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. Effective contraception should be used during treatment and for at least 2 months after the last dose.
Report any new or worsening hypertension, severe headache, or blurred vision.,Notify your doctor if you experience unusual bleeding, bruising, or blood in urine or stool.,Avoid invasive dental procedures and inform your dentist about this medication.,Use reliable contraception during treatment and for at least 6 months after the last dose.,Seek immediate medical attention for sudden chest pain, shortness of breath, or leg swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VECTIBIX vs VEGZELMA, answered by our medical review team.
VECTIBIX is a Antineoplastic Monoclonal Antibody that works by Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.. VEGZELMA is a Antineoplastic Monoclonal Antibody that works by VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VECTIBIX and VEGZELMA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VECTIBIX is: 6 mg/kg IV every 14 days.. The standard adult dose of VEGZELMA is: Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VECTIBIX and VEGZELMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VECTIBIX is classified as Category C. Pregnancy Category C. Panitumumab is an IgG2 monoclonal antibody; IgG crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EG. VEGZELMA is classified as Category C. VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratog. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.